CMS preliminary 2025 MA rates ~160 bps worse than Humana's flat-rate expectation; 2025 outlook unchanged

HUMANA INC

CMS estimates average MA benchmark funding decrease of 0.16% in Advance Notice.
Humana's analysis shows its benchmark change ~160 bps worse than expected flat rate.
Primary drivers: proposed effective growth rate restatements and normalization factors.
Company reaffirms 2025 Adjusted EPS growth outlook of $6 to $10.
Final rates expected April 1, 2024; Humana will provide formal comments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.